HC Wainwright Lifts Earnings Estimates for Dare Bioscience

Dare Bioscience, Inc. (NASDAQ:DARE) – HC Wainwright boosted their Q3 2026 earnings per share (EPS) estimates for Dare Bioscience in a report released on Friday, August 14th. HC Wainwright analyst D. Tsao now forecasts that the biotechnology company will earn $0.10 per share for the quarter, up from their previous forecast of $0.09. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Dare Bioscience’s current full-year earnings is ($0.97) per share. HC Wainwright also issued estimates for Dare Bioscience’s Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.46) EPS, FY2027 earnings at ($0.31) EPS, FY2028 earnings at $0.18 EPS and FY2029 earnings at $1.31 EPS.

Dare Bioscience (NASDAQ:DARE) last announced its quarterly earnings data on Thursday, August 13th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.10. The company had revenue of $0.19 million for the quarter, compared to analysts’ expectations of $0.00 million. Dare Bioscience had a negative net margin of 803.80% and a negative return on equity of 748.30%.

DARE has been the topic of a number of other reports. Benchmark restated a “buy” rating on shares of Dare Bioscience in a research note on Monday. Wall Street Zen upgraded shares of Dare Bioscience to a “hold” rating in a report on Saturday, May 23rd. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Dare Bioscience in a research note on Friday, July 17th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Dare Bioscience Stock Down 12.9%

Shares of NASDAQ:DARE opened at $0.81 on Tuesday. Dare Bioscience has a 52 week low of $0.77 and a 52 week high of $3.78. The company has a 50-day moving average price of $1.72 and a 200 day moving average price of $1.87. The company has a market cap of $12.22 million, a P/E ratio of -1.16 and a beta of 1.08.

Hedge Funds Weigh In On Dare Bioscience

Hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new position in Dare Bioscience during the third quarter worth about $37,000. Raymond James Financial Inc. increased its stake in shares of Dare Bioscience by 810.6% during the 3rd quarter. Raymond James Financial Inc. now owns 15,334 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 13,650 shares in the last quarter. Finally, LPL Financial LLC acquired a new position in shares of Dare Bioscience during the 4th quarter worth approximately $28,000. 6.70% of the stock is currently owned by hedge funds and other institutional investors.

Dare Bioscience Company Profile

Dare Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use.

In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery.